GSK plc

GSK

GB00BN7SWP63

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 08:38 am EDT

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.17 GBP

Average target price

19.88 GBP

Spread / Average Target

+31.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+4.61%	80.36B
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:28 2024-07-12 am EDT			5-day change	1st Jan Change
1,517 ^GBX	+0.80%		+0.40%	+4.61%

02:16pm	GSK to Move Global Headquarters in London	MT
12:20pm	GSK moves to new global headquarters in return to central London	AN

GSK to Move Global Headquarters in London	08:16am	MT
GSK moves to new global headquarters in return to central London	06:20am	AN
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	Jul. 11	MT
GSK: first shipments of flu vaccines to the USA	Jul. 11	CF
GSK Begins Shipping Flu Vaccines Flulaval, Fluarix	Jul. 11	MT
GSK: EXPECTS TO DISTRIBUTE OVER 36 MLN DOSES OF ITS TRIVALENT IN…	Jul. 11	RE
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season	Jul. 11	CI
GSK : Deutsche Bank reiterates its Buy rating	Jul. 10	ZD
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	Jul. 08	RE
UBS Downgrades GSK to Neutral From Buy	Jul. 08	MT
That's not so bad, is it?	Jul. 08
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment	Jul. 08	MT
UBS Downgrades GSK to Neutral from Buy, Cuts PT	Jul. 08	MT
ITeos Therapeutics, Inc. Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK	Jul. 08	CI
UBS cuts GSK; RBC raises Melrose Industries	Jul. 08	AN
GSK : UBS downgrades its recommendation	Jul. 08	CF
Carlsberg to buy Britvic in GBP3.3 billion deal	Jul. 08	AN
GSK : Reduced to Neutral by UBS	Jul. 08	ZD
GSK: FIRST SINGLE-DOSE MEDICINE TO PREVENT RELAPSE OF P. VIVAX M…	Jul. 05	RE
GSK launches antimalarial drug in Thailand and Brazil	Jul. 05	CF
Citigroup Trims GSK PT, Maintains Buy Rating	Jul. 05	MT
Jefferies cuts Softcat to 'underperform'	Jul. 05	AN
GSK : Deutsche Bank keeps its Buy rating	Jul. 04	ZD
GSK : UBS keeps its Buy rating	Jul. 04	ZD
Health Stocks Slip in Risk-On Trade -- Health Care Roundup	Jul. 03	DJ